Indian pharma industry headwinds in remission: ICRA

Indian pharma industry headwinds in remission: ICRA

New Delhi: ICRA expects the revenues of the sample set of 25 Indian pharmaceutical companies (which account for ~60 per cent of the overall Indian pharmaceutical industry) to grow by 7-9 per cent in FY2024, post a YoY growth of 10 per cent in FY2023. The same will be...